Peptide therapy for Black men: separating hype from evidence

What did @ray_f_baby25 actually say?

Ray, who turns 40 this year, credits "pips" (peptides) as the probable reason he has abs for the first time after 15-17 years of serious lifting. He says he's been in the peptide space about six months, built a community of people sharing information, and invites others, specifically Black men who feel nervous asking, to reach out with questions. He's careful not to promise outcomes: "Should you be on pips? I don't know."

What he does not say: he doesn't name specific peptides, doses, protocols, or make any disease-related claims. This is almost entirely a community-building video with one soft attribution claim buried in the middle. That matters for how we evaluate it.

Does the science back this up?

The honest answer is: it depends entirely on which peptide he's actually using, and he never tells us. The "peptide" umbrella covers compounds with wildly different mechanisms and evidence bases.

If he's using GLP-1 receptor agonists (like semaglutide), the body composition data is real. The STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) showed an average 14.9% body weight reduction in adults with obesity using semaglutide versus 2.4% with placebo. That's not nothing, and for someone who's always been strong but never lean, a GLP-1 could plausibly explain new abdominal definition.

If he means growth hormone secretagogues like ipamorelin or CJC-1295, the evidence gets thinner. Small studies show modest lean mass preservation and some fat reduction, but nothing approaching the GLP-1 effect size. If he means BPC-157 or TB-500, those are primarily recovery-oriented peptides with almost no human RCT data on body composition at all.

The claim is soft enough to be defensible. The problem is the vagueness itself.

What did they get wrong (or right)?

Credit where it's due: Ray is one of the more epistemically honest peptide influencers you'll find on TikTok. He says "probably" twice when attributing his results to peptides. He does not say "this will work for you." He acknowledges he doesn't know if you should use them. That's a lower bar than most in this space, but he clears it.

What he gets wrong, or at least incomplete: "exchanging information" in unregulated peer-to-peer networks is not medical guidance, and framing it as community care doesn't change the risk profile. Peptides sourced outside a licensed prescriber and pharmacy have no verified purity or dosing accuracy. A 2021 analysis by Venhuis et al. in Drug Testing and Analysis found significant labeling inaccuracies in research-chemical peptides sold online. People following informal advice from gym contacts, even well-meaning ones, have no way to account for contraindications, drug interactions, or individual variation.

The implicit suggestion that community information-sharing is a substitute for clinical oversight is the one thing worth pushing back on here.

What should you actually know?

If you're a 40-year-old man curious about peptide therapy, the first question isn't "which peptides should I use" but "what's actually driving my body composition issue." Testosterone declines, cortisol patterns, insulin sensitivity, sleep quality, and training history all shape what abs look like at 40. Attributing a result to a peptide without controlling for any of those variables is not science, it's anecdote with a confident tone.

That doesn't mean peptides are useless. Some have legitimate clinical use cases under medical supervision. GLP-1 receptor agonists are FDA-approved for specific indications. Growth hormone peptides are prescribed off-label by licensed clinicians for documented deficiencies. The relevant question is whether your use case justifies the compound, and that answer requires labs, a medical history review, and a licensed prescriber, not a TikTok DM.

FormBlends operates under telehealth regulations specifically because this stuff requires oversight. If you're curious whether peptide therapy is appropriate for you, that conversation starts with a provider, not a comment section.